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An Economic Drag*Geoffrey D. Barnes, MD, MSC, Elizabeth A. Jackson, MD, MPHP eripheral artery disease (PAD) is a signiﬁcantpublic health concern with more than 200million adults diagnosed with PAD globally
(1). In the United States, the annual prevalence of
PAD is estimated at 12.3% (on the basis of national in-
surance claims) or 8.5 million individuals age $40
years (1). PAD is associated with signiﬁcant increased
risk for mortality. An estimated $4.37 billion in health
care expenditures related to PAD were spent in 2001
alone (2) and increases in health care utilization
related to PAD during the past decade translate into
even higher costs in recent years. One of the strongest
risk factors for PAD is tobacco use, which carries a 3-
to 4-fold increased risk for PAD, often presenting as
severe disease (1).
Unlike PAD, rates of tobacco use have declined by
26% since the late 1990s; now smokers are estimated
to make up 18% of the American population (1).
Despite the declining numbers of adults who smoke,
health care costs related to tobacco use are stag-
gering. Annual tobacco-attributed costs are estimated
at $133 billion to $176 billion for direct-medical costs
and an additional $151 billion for lost productivity (1).SEE PAGE 1566The paper by Duval et al. (3) in this issue of the
Journal supports prior studies showing high health
care utilization among PAD patients (2,4). The present
study adds to our current understanding by discrimi-
nating health care costs for PAD patients who smoke
compared to nonsmoking PAD patients (3). The*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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Policy and Innovation, University of Michigan Medical Center, Ann Arbor,
Michigan. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.authors used data from Minnesota’s Blue Cross Blue
Shield claims database collected for 2011. Of the
22,203 patients with PAD, 1,995 (9.0%) were identiﬁed
as tobacco users (lower than national estimates). One-
half of all tobacco users experienced hospitalizations
during the study period, a 35% higher rate compared
to nontobacco users with PAD. Smokers with PAD
were more frequently admitted to the hospital for
atherosclerotic diagnoses, acute myocardial infarc-
tion, and coronary heart disease and also were found
to have a higher short-term cost ($64,041 vs. $45,918)
compared to nonsmokers. The authors concluded that
tobacco use among PAD patients is associated with a
signiﬁcant increase in PAD-related hospitalizations,
atherosclerotic procedures, and health care costs. The
costs were on the basis of 1-year follow-up; thus it is
likely the long-term costs for PAD smokers are also
signiﬁcantly higher compared to PAD nonsmokers.
The authors performed detailed and thorough
analyses to identify the tobacco user and nonuser
cohorts, yet (as the authors themselves acknowledge)
underestimation of smoking status was most likely
present given the use of claims data. Notwithstanding
this limitation, the impact of smoking on the leading
hospital discharge diagnoses was striking. The num-
ber 1 reason for hospitalization among tobacco users
was atherosclerotic disease, whereas nonsmokers had
7 to 9 other more common diagnoses. As with any
observational study, care must be taken not to
confuse correlation with causation. Whereas prior
studies have accounted for the costs associated with
either PAD diagnosis or tobacco use, this study
quantiﬁes the costs when the 2 are combined. In do-
ing so, this study raises the issue of ﬁnancing effec-
tive tobacco cessation interventions.
For all patients, the U.S. Preventative Services Task
Force recommends the use of the 5 A’s whenmanaging
tobacco using patients: 1) assess behaviors, beliefs,
and knowledge; 2) advise about health risks and the
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1576beneﬁt of change; 3) agree on a collaborative set of
goals; 4) assist with support and pharmacotherapy;
and 5) arrange follow up (5,6). However, this assess-
ment is not regularly used by clinicians (7,8).
Currently an estimated one-half of all patients who
smoke report that their physician did not counsel
them regarding tobacco cessation. Improved utiliza-
tion and efﬁcacy of interventions are critical (1).
Electronic medical record systems with prompts to
record and treat tobacco abuse have been associated
with increased use of tobacco cessation referral pro-
grams (9), andmay improve rates of smoking cessation
counseling by clinicians. Similarly, use of state-based
phone and internet resources have been shown to
improve 30-day tobacco abstinence rates (10), and can
be used to provide targeted messages to speciﬁc pop-
ulations such as those with PAD. Lastly, use of phar-
macologic interventions, such as nicotine patches,
have shown efﬁcacy and should be considered as a
critical tool for smoking cessation programs (11).
It remains simplistic to think that a magic bullet
exists to treat all patients who use tobacco. In 2010,
we described a 1-size-ﬁts-all approach to tobacco
cessation “both naïve and biologically implausible”
(12). Assessing a patient’s willingness to quit, and any
potential barriers they have, will help to personalize
tobacco cessation assistance. Targeting interventions
to speciﬁc populations, such as those with PAD, may
enhance smoking cessation interventions. In a recent
randomized trial of 124 PAD patients who smoked,
abstinence from tobacco use was greatly improved at
12 months when a tailored PAD-speciﬁc intervention
was delivered (13). Health care policies that improveaccess and reimbursement for nicotine replacement
and counseling are needed, particularly for groups
with high health care utilization (14). Financial in-
centives for tobacco cessation may also be part of
the solution. Use of a rewards-based model over a
deposit-based program showed abstinence rates up to
16% at 6 to 12 months (15,16).
On the basis of the results of the study by Duval
et al.(3), it would seem logical to deﬁne PAD patients
as a highest-risk group for adverse outcomes and thus
increased health care costs; therefore making it an
important population to target for nicotine replace-
ment coverage and/or ﬁnancial incentives for tobacco
abstinence. This is especially paramount because the
increased health care costs accrued by tobacco users
are funded by the population at large. Therefore, all
citizens have a vested interest in reducing this health
care burden.
One might suggest that concluding that high costs
related to smoking among PAD patients is obvious,
but it is the magnitude of the cost compared to non-
smoking PAD patients over a relatively short time
period that is an important message. This study high-
lights the urgent need for smoking cessation among
PAD patients and getting patients to quit has the po-
tential to greatly improve carewhereas potentially saving
signiﬁcant health care dollars over the long term.
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